Recent regulatory guidance underscores the risks associated with compounding GLP-1s using additives such as B12 or glycine
A clinical study published in the New England Journal of Medicine in 2024 (4) showed that, in people with excess fatty liver with mild to moderate fibrosis , administration of semaglutide once a week for 240 weeks was correlated with: improvement in liver composition and inflammation without worsening of fibrosis in more than 60% of cases, compared with approximately 34% of subjects on placebo reduction in scar tissue without worsening of steatohepatitis in more than 36% of patients, compared with around 22% of those on placebo resolution of steatohepatitis with a reduction in fibrosis in 32.7% of patients, compared with 16.1% in the placebo group average reduction in body weight of 10.5%, compared with just 2.0% on placebo The mechanisms that could explain these results From a medical point of view, these effects on liver health could be explained by several complementary mechanisms: a general reduction in body fat , particularly visceral fat in the abdomen and liver, a criterion often associated with improvements in liver parameters (5) a reduction in oxidative stress , known to damage liver cells (6) Although potentially interesting for supporting liver function , GLP-1 agonists are drug treatments that can have side effects (7)
Clinic is manufactured under GMP, HACCP, and ISO 9001:2015 standards, with third-party lab verification for purity, sterility, endotoxin, and heavy metal testing
Exposure to hyperandrogen drives ovarian dysfunction and fibrosis by activating the NLRP3 inflammasome in mice
